Status:
TERMINATED
HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborating Sponsors:
Aventis Pharmaceuticals
Conditions:
HIV Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
HIV-specific immune responses are preserved in patients treated early during primary infection.The trial evaluated whether the addition to HAART of IL-2 alone or combined with an immunization procedur...
Detailed Description
HIV-specific immune responses are preserved in patients treated early during primary infection. The trial evaluated whether the addition to HAART of IL-2 alone or combined with an immunization procedu...
Eligibility Criteria
Inclusion
- History of symptomatic HIV primary infection with p24 positive or incomplete Western Blot
- Treatment beginning before 4W after the first primary infection serology
- HAART with IP or NNRTI since one year, wtih no change since 3 months
- Viral load below 50 cp since 6 months
- PN over 1000/mm3;Hb over 10.5g/l;Platelets over 75000/mm3, creatinine below 1.5N; transaminases below 2.5N
Exclusion
- Vaccination or chemotherapy or corticosteroid since 3 months
- Evolutive cancer
- pregnancy or breastfeeding
Key Trial Info
Start Date :
August 1 2000
Trial Type :
INTERVENTIONAL
End Date :
February 1 2004
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00196651
Start Date
August 1 2000
End Date
February 1 2004
Last Update
September 20 2005
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.